Original Source(s)
Related Content
New Tool Clarifies CI Eligibility
“Ongoing refinement and prospective validation will be important for successful integration into clinical practice,” the researchers wrote.
by Doug Brunk
February 3, 2026
-
4 min
FDA Okays Weekly Option in Achondroplasia
Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
March 2, 2026
-
2 min